John Higuchi is a co-founder and serves on the Board of Directors of Spriaso, LLC, a specialty pharmaceutical company in Utah with an FDA-approved combination drug, respiratory therapeutics product—Tuxarin-ER—which is scheduled to be launched in the fall of 2021. Higuchi also co-founded and serves on the Board of Directors of Lipocine Inc., a publicly traded, Utah-based men’s and women’s health company, addressing various important diseases such as NASH, liver cirrhosis, forms of depression, and preterm birth. Lipocine’s first product—Tlando, a fixed oral dose of testosterone (not requiring titration)—is expected to be commercialized in 2022. Higuchi also currently serves as CEO of Aciont Inc., a mid-clinical staged ocular therapeutics company in Utah developing a non-invasive topical application device to deliver different types of drug molecules to the front and back of the eye. Higuchi received a Bachelor of Science in Chemistry from Hope College and an M.B.A. and Master of Science in Information Systems from The George Washington University.